Justin M. Allen
Research Subjects
Justin M. Allen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Alexa B. Schrock
Foundation Medicine, Boston, MA
43 shared publications - Alexander Drilon
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
36 shared publications - Andreas M. Heilmann
Foundation Medicine, Inc., Cambridge, Massachusetts
36 shared publications - Bob T. Li
Memorial Sloan Kettering Cancer Center, New York, USA
36 shared publications - Dazhi Liu
Memorial Sloan Kettering Cancer Center 1 Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine New York, New York
36 shared publications - Justin Jee
Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
36 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
SUPPLEMENTARY MATERIALS & METHODS Foundation Medicine Comprehensive Genomic Profiling
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
SUPPLEMENTARY MATERIALS & METHODS Foundation Medicine Comprehensive Genomic Profiling
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Figure S10. HER2-Directed Therapy Response Modifying Alterations In Select Cancers (Related To Figure 4) Co-occurrence of alterations that have been reported to impact response to HER2-directed therapies (mAB, TKI, ADC) in tumors with ERBB2 amplification or ERBB2 activating mutations including TP53 MUT, PIK3CA MUT, CCNE1 AMP, RB1 MUT/DEL, PTEN MUT/DEL, ERBB3 AMP/MUT, EGFR MUT, MET AMP/Ex14 MUT, and IGF1R AMP. Patients with multiple ERBB2 alteration types (e.g., AMP + MUT) were excluded from the analysis. ADC, Antibody-Drug Conjugate; AMP, Amplification; mAB, Monoclonal Antibodies; MUT, Mutation (SNV, Indel); TKI, Tyrosine Kinase Inhibitor.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Figure S10. HER2-Directed Therapy Response Modifying Alterations In Select Cancers (Related To Figure 4) Co-occurrence of alterations that have been reported to impact response to HER2-directed therapies (mAB, TKI, ADC) in tumors with ERBB2 amplification or ERBB2 activating mutations including TP53 MUT, PIK3CA MUT, CCNE1 AMP, RB1 MUT/DEL, PTEN MUT/DEL, ERBB3 AMP/MUT, EGFR MUT, MET AMP/Ex14 MUT, and IGF1R AMP. Patients with multiple ERBB2 alteration types (e.g., AMP + MUT) were excluded from the analysis. ADC, Antibody-Drug Conjugate; AMP, Amplification; mAB, Monoclonal Antibodies; MUT, Mutation (SNV, Indel); TKI, Tyrosine Kinase Inhibitor.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Table S1. Histology Breakdown Of Top 5 ERBB2 MUT Cancer Types
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Table S1. Histology Breakdown Of Top 5 ERBB2 MUT Cancer Types
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Figure S6. ERBB2 Mutation Clonality Distribution of clonal fraction (VAF/TP) for ERBB2 mutation classes across select cancers. A dashed line at clonal fraction of 0.25 (25%) is shown as an estimated threshold for clonality1,2. ECD, Extracellular Domain; KD, Kinase Domain; TMD, Transmembrane Domain; TP, Computational Tumor Purity; VAF, Variant Allele Frequency. 1Sottoriva A, Graham TA. A pan-cancer signature of neutral tumor evolution. bioRxiv. 2015;014894. 2Bozic I, Gerold JM, Nowak MA. Quantifying Clonal and Subclonal Passenger Mutations in Cancer Evolution. PLoS Comput Biol. 2016;12:e1004731.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Figure S6. ERBB2 Mutation Clonality Distribution of clonal fraction (VAF/TP) for ERBB2 mutation classes across select cancers. A dashed line at clonal fraction of 0.25 (25%) is shown as an estimated threshold for clonality1,2. ECD, Extracellular Domain; KD, Kinase Domain; TMD, Transmembrane Domain; TP, Computational Tumor Purity; VAF, Variant Allele Frequency. 1Sottoriva A, Graham TA. A pan-cancer signature of neutral tumor evolution. bioRxiv. 2015;014894. 2Bozic I, Gerold JM, Nowak MA. Quantifying Clonal and Subclonal Passenger Mutations in Cancer Evolution. PLoS Comput Biol. 2016;12:e1004731.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Figure S4. ERBB3 Mutation Landscape Of Select Cancers Shown for each cancer type are (Left) the distribution of mutations across key HER3 protein domains, (Middle) lollipop plot showing the location and incidence of mutations across the HER3 protein (NM_001982) with the 5 most frequently mutated codons labeled, and (Right) plot showing distribution of mutations among the 10 most frequently mutated codons. The number of mutations is indicated. AA, Amino Acid; ECD, Extracellular Domain; KD, Kinase Domain; TMD, Transmembrane Domain.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Figure S4. ERBB3 Mutation Landscape Of Select Cancers Shown for each cancer type are (Left) the distribution of mutations across key HER3 protein domains, (Middle) lollipop plot showing the location and incidence of mutations across the HER3 protein (NM_001982) with the 5 most frequently mutated codons labeled, and (Right) plot showing distribution of mutations among the 10 most frequently mutated codons. The number of mutations is indicated. AA, Amino Acid; ECD, Extracellular Domain; KD, Kinase Domain; TMD, Transmembrane Domain.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Figure S3. ERBB2 Mutation Landscape Of Select Cancers Shown for each cancer type are (Left) the distribution of mutations across key HER2 protein domains, (Middle) lollipop plot showing the location and incidence of mutations across the HER2 protein (NM_004448) with the 5 most frequently mutated codons labeled, and (Right) plot showing distribution of mutations among the 10 most frequently mutated codons. The number of mutations is indicated. AA, Amino Acid; ECD, Extracellular Domain; KD, Kinase Domain; TMD, Transmembrane Domain.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Figure S3. ERBB2 Mutation Landscape Of Select Cancers Shown for each cancer type are (Left) the distribution of mutations across key HER2 protein domains, (Middle) lollipop plot showing the location and incidence of mutations across the HER2 protein (NM_004448) with the 5 most frequently mutated codons labeled, and (Right) plot showing distribution of mutations among the 10 most frequently mutated codons. The number of mutations is indicated. AA, Amino Acid; ECD, Extracellular Domain; KD, Kinase Domain; TMD, Transmembrane Domain.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Table S2. Histology Breakdown Of Top 5 ERBB3 MUT Cancer Types
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Table S2. Histology Breakdown Of Top 5 ERBB3 MUT Cancer Types
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Figure S11. Pan-Tumor Landscape Of ERBB2 Activating Alterations Detected In The MSKCC Clinicogenomic Cohort a) Prevalence of ERBB2 activating alterations (known or likely functional significance) across solid tumors in the MSKCC clinicogenomic cohort. ‘Multiple’ includes patients with AMP + MUT, AMP + RE, MUT + RE, AMP + MUT + RE and patients with >1 MUT. b) Cancer type distribution of ERBB2 MUT tumors. AMP, Amplification (CN ≥ 6); MUT, Mutation (SNV, Indel); RE, Rearrangement.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Figure S11. Pan-Tumor Landscape Of ERBB2 Activating Alterations Detected In The MSKCC Clinicogenomic Cohort a) Prevalence of ERBB2 activating alterations (known or likely functional significance) across solid tumors in the MSKCC clinicogenomic cohort. ‘Multiple’ includes patients with AMP + MUT, AMP + RE, MUT + RE, AMP + MUT + RE and patients with >1 MUT. b) Cancer type distribution of ERBB2 MUT tumors. AMP, Amplification (CN ≥ 6); MUT, Mutation (SNV, Indel); RE, Rearrangement.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Figure S8. Co-Alteration Landscape Of ERBB2 Mutated Tumors In Select Cancers The prevalence of oncogenic co-alterations was compared for ERBB2 MUT (excluding samples w/ ERBB2 co-amplification) versus ERBB2 WT (non-mutated and non-amplified) a) NSCLC, b) Breast, c) CRC, d) Bladder, e) GEC, f) MSS CRC, and g) MSS GEC tumor samples profiled using tissue CGP. Only genes altered in at least 50 tumors and targeted across all tissue CGP assay versions were included. For each gene, mutations (SNVs, Indels), rearrangements, and copy number changes of known or likely functional significance detected using our assay were included. Genes highlighted in the National Comprehensive Cancer Network (NCCN) Guidelines as molecular drivers as well as genes altered at a high prevalence (≥10%) in either cohort are labeled for each volcano plot if a statistically significant difference was observed (p < 0.05, threshold indicated by dashed line). ERBB3, if statistically significant, is also labeled. Fisher’s Exact Test was performed to assess patterns of co-occurrence/mutual exclusivity between ERBB2 and other genes. P values were corrected using the Benjamini-Hochberg FDR method. MSS, Microsatellite Stable.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Figure S8. Co-Alteration Landscape Of ERBB2 Mutated Tumors In Select Cancers The prevalence of oncogenic co-alterations was compared for ERBB2 MUT (excluding samples w/ ERBB2 co-amplification) versus ERBB2 WT (non-mutated and non-amplified) a) NSCLC, b) Breast, c) CRC, d) Bladder, e) GEC, f) MSS CRC, and g) MSS GEC tumor samples profiled using tissue CGP. Only genes altered in at least 50 tumors and targeted across all tissue CGP assay versions were included. For each gene, mutations (SNVs, Indels), rearrangements, and copy number changes of known or likely functional significance detected using our assay were included. Genes highlighted in the National Comprehensive Cancer Network (NCCN) Guidelines as molecular drivers as well as genes altered at a high prevalence (≥10%) in either cohort are labeled for each volcano plot if a statistically significant difference was observed (p < 0.05, threshold indicated by dashed line). ERBB3, if statistically significant, is also labeled. Fisher’s Exact Test was performed to assess patterns of co-occurrence/mutual exclusivity between ERBB2 and other genes. P values were corrected using the Benjamini-Hochberg FDR method. MSS, Microsatellite Stable.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Figure S1. ERBB2/ERBB3 Amplification Pan-Tumor Landscape The distribution of amplification ratios for tumors with a) ERBB2 and b) ERBB3 amplification in tissue biopsies as assessed by FoundationOneCDx is shown. Amplification ratio is equal to the ratio of the modeled gene copy number to sample ploidy. Tumor types representing the highest proportion of ERBB2 or ERBB3 mutated tumors, respectively, which were the subject of focused analysis in this study are highlighted.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Supplementary Figure S1. ERBB2/ERBB3 Amplification Pan-Tumor Landscape The distribution of amplification ratios for tumors with a) ERBB2 and b) ERBB3 amplification in tissue biopsies as assessed by FoundationOneCDx is shown. Amplification ratio is equal to the ratio of the modeled gene copy number to sample ploidy. Tumor types representing the highest proportion of ERBB2 or ERBB3 mutated tumors, respectively, which were the subject of focused analysis in this study are highlighted.